Persistence Capital to Hold Majority Stake in Warnex | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Warnex said this week that the conversion of debentures into shares of the company will provide Persistence Capital Partners with a nearly 52 percent stake in the firm.

The conversion of C$725,000 in principal amount of debentures into an aggregate of 46,178,344 common shares of Warnex was set to take place yesterday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.